NCT05504265 Perioperative Analgesia Modes in Minimally Invasive Esophagectomy
| NCT ID | NCT05504265 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
| Condition | Esophageal Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 102 participants |
| Start Date | 2022-10-10 |
| Primary Completion | 2025-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 102 participants in total. It began in 2022-10-10 with a primary completion date of 2025-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study was designed to compare analgesic efficacy and safety of different perioperative analgesic modes in minimally invasive esophagectomy for esophageal cancer.
Eligibility Criteria
Inclusion Criteria: * 18-75 years; * Patients underwent laparoscopic and thoracoscopic or robotic-assisted minimally invasive esophagectomy ; * Informed consent. Exclusion Criteria: * Has a history of cholecystitis or urolithiasis within 3 months; * Has a history of atherothrombosis (peripheral arterial disease), stroke, myocardial infarction; * With lung diseases, such as pneumonia, atelectasis, emphysema, pulmonary bullae, etc; * Preoperative cardiac function grade ≥ III or coronary artery stenosis; * Preoperative indwelling of a thoracic drainage tube; * Long-term heavy drinker(heavy drinking was defined as follows: for men, consuming more than 4 drinks on any day or more than 14 drinks per week; For women, consuming more than 3 drinks on any day or more than 7 drinks per week); * Opioid-tolerant patients(defined as those who have been taking, for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid); * With painful skin complications, such as rashes and blisters; * Conversion to open surgery; * The postoperative ventilation function was limited, or the duration of endotracheal intubation was more than 24h.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05504265 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Esophageal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05504265 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT05504265 currently recruiting?
Yes, NCT05504265 is actively recruiting participants. Contact the research team at zhuzhixiang2010@163.com for enrollment information.
Where is the NCT05504265 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT05504265 clinical trial?
NCT05504265 is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. The trial plans to enroll 102 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.